Compare Entegris Inc (ENTG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs BIO-TECHNE Corp — how do they compare? Entegris Inc trades at $165 (market cap $25.41B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Entegris Inc is far larger — about 2.2× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and BIO-TECHNE Corp for 63 Days on average.
| ENTG | TECH | |
|---|---|---|
Market Cap | $25.41B | $11.37B |
Volume | 2,160,232 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $184.00 | $72.61 |
52-Week Low | $68.80 | $43.31 |
Typical Hold Time | 41 Days | 63 Days |
Enterprise Value | $28.62B | $11.40B |
Dividend Yield | 0.24% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $162.19, down 2.82% today, with strong technical momentum as moving averages signal bullish alignment. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $0.93 versus $0.82, driven by AI-related semiconductor demand. Revenue remains stable at $3.2B in 2025, while net income margin improved to 9.18% in 2026 projections. Recent institutional buying includes BlackRock's $3.68 billion position, reflecting confidence in Entegris' advanced materials leadership.
Outlook remains positive with analyst consensus target of $182.43 suggesting 12.5% upside, supported by 70% buy ratings. Key risks include high valuation multiples (P/E 83.16) and semiconductor cycle sensitivity. The upcoming Q3 earnings on October 29, 2026, and Investor Day on November 9, 2026, are critical catalysts for confirming growth trajectory amid competitive pressures.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
